The Medical Minute: Acoustic neuromas -- benign but lethal

October 13, 2010 By Sandra Brettler

( -- Have you had a gradual hearing loss in one ear? Have you noticed worsening ringing in one ear? Do you find yourself getting dizzy or feeling off-balance just standing still? Have you “switched ears” when talking on the phone? These may all be signs that you might need to have your hearing checked. They may also be symptoms of a benign, or slow growing tumor on the nerve that plays a large part in your hearing and balance.

Unilateral , difficulty maintaining your balance, and difficulty adjusting your eyes may all be subtle symptoms of a small called an acoustic neuroma. This type of tumor grows from the Schwann cells in the eighth cranial nerve known as the vestibulocochlear nerve. This nerve originates in the brainstem and is one of the components responsible for your hearing and balance. No one quite knows why these tumors develop, but they develop very slowly over time, often taking several years to finally cause any symptoms of hearing loss, ringing in the ear, or balance problems. These tumors begin near the entrance to the internal auditory canal and grow into the petrous bone as well as more internally towards the brainstem. In some people, they can be quite large before they become detected.

For many years, the treatment of these types of tumors included “watchful waiting,” surgery, or localized radiation. Within the past several years, stereotactic radiosurgery, or Gamma Knife, has become the preferred method of treatment for many of these tumors. Sometimes, these tumors are found incidentally, during routine testing for other types of neurologic diseases or problems (headaches, head injuries, etc.). Not all people who have acoustic neuromas develop symptoms, nor do all patients need to be treated.

“Watchful waiting” means that the tumor is monitored through the use of magnetic resonance imaging (MRI) on a yearly basis to see if it is growing. Although some tumors grow along the nerve slowly, physicians can choose to watch it over the course of several years to see if a given tumor is actively growing or not. Many non-growing tumors do not need treatment, but careful follow-up is necessary to detect future growth. Certainly if symptoms arise, then treatment would be indicated.

Surgical intervention is indicated if the tumor is excessively large or compresses the brainstem to a problematic extent. Surgery can often take several hours and require several specialists to perform the surgery (usually a neurosurgeon and an otolaryngologist, commonly known as an ear, nose, and throat specialist). Hearing loss is almost a certainty, though sometimes it can be spared if the tumor is of a small or moderate size. Surgical intervention will require a hospital stay of less than a week, and a recovery of up to about 8-12 weeks.

Standard radiation treatments may also be an option for some patients. Depending on the size of the tumor, some surgeons have suggested that patients undergo traditional radiation to assist in shrinking the tumor before a surgical procedure. This would entail the delivery of low-dose, focused radiation on a daily basis for several weeks to the tumor area. This type of treatment has somewhat fallen out of favor and is used rarely today.

Stereotactic radiosurgery can also be utilized and in recent years, has become the preferred method of treatment for many patients. This is most often and most accurately delivered using the Gamma Knife. This treatment consists of precisely delivering high-dose radiation to the tumor in a single outpatient treatment that lasts about 2-4 hours. The treatment controls the tumor in the vast majority of cases and is extremely safe. After the treatment, there is little recovery, minimal complications and one could return to work the next day, or even a few hours after the procedure. The dose of radiation causes the tumor to stop growing, and in some cases, the tumor can even shrink over time.

Related Stories

Recommended for you

Data-driven malaria early warning system could predict outbreaks months in advance

October 24, 2017
A Johns Hopkins University scientist is part of a team working on a method to predict malaria outbreaks months in advance, potentially giving public health officials a chance to protect people from a disease that poses a ...

Novel therapies for multidrug-resistant bacteria

October 23, 2017
During this innovative study published in PLOS One, researchers found that novel classes of compounds, such as metal-complexes, can be used as alternatives to or to supplement traditional antibiotics, which have become ineffective ...

Key discoveries offer significant hope of reversing antibiotic resistance

October 23, 2017
Resistance to antibiotics is becoming increasingly prevalent and threatens to undermine healthcare systems across the globe. Antibiotics including penicillins, cephalosporins and carbapenems are known as β-lactams and are ...

Exploring how herpes simplex virus changes when passed between family members

October 22, 2017
A new study explores how herpes simplex virus might change when passed from one individual to another, information that may prove useful in future development of therapeutics and vaccines. This rare glimpse into a transmission ...

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.